Benzimidazoles as Anti-VEGFRs: A Review

Author(s)

Ankita, P., Romana, Z., Sanjar, A.

Author's Affiliation

Abstract

Angiogenesis can be regarded as a hallmark to deal with different type of cancers as they help tumors proliferate and metastasize. A major angiogenic inducer released by many tumors, vascular endothelial growth factor (VEGF) predominantly dimerizes with the VEGFR2 receptor. The same can be used both as a surrogate biomarker for biological drug activity and a promising target for inhibitors. But, inhibitors are quickly hijacked by tumor cells in more invasive and aggressive forms resulting in resistance and hence poor drug delivery towards tumors. Understanding the current problem there is an urge to design a multi-targeted molecule with appropriate pharmacophoric features to enhance potency along with reduced toxicity and resistance. The present review focuses on synthesis, characterization and biological activity of novel benzimidazole derivatives based on generated Pharmacophore model. These drugs will serve our purpose of discovering novel anticancer agents against the VEGFR that are overexpressed and their capability to decrease the resistance.

Keywords

Benzimidazole, VEGFR, VEGF, Angiogenesis, HIF, Anti-VEGFRs

Cite This Article

Ankita, P., Romana, Z., Sanjar, A. (2018). Benzimidazoles as Anti-VEGFRs: A Review. International Journal for Pharmaceutical Research Scholars (IJPRS), 6(1), 82-95.